UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

		FORM 8-K	
	The	CURRENT REPORT ursuant to Section 13 or 15(d) of e Securities Exchange Act of 1934	
	Date of Report (Date of earl	iest event reported): December 1, 202	21 (December 1, 2021) ———
		Humana Inc.	
	(Exact I	name of registrant as specified in its charter)	
	Delaware (State or other jurisdiction of incorporation)	001-5975 (Commission File Number)	61-0647538 (IRS Employer Identification No.)
		est Main Street, Louisville, Kentucky 40202 ess of principal executive offices, including zip code)	
	(Re	(502) 580-1000 gistrant's telephone number, including area code)	
	(Former	r name or former address, if changed since last report)	
	(Former ek the appropriate box below if the Form 8-K filing is wing provisions:		ligation of the registrant under any of the
	k the appropriate box below if the Form 8-K filing is	intended to simultaneously satisfy the filing ob	ligation of the registrant under any of the
follo	ek the appropriate box below if the Form 8-K filing is wing provisions:	intended to simultaneously satisfy the filing ob the Securities Act (17 CFR 230.425)	ligation of the registrant under any of the
follo	k the appropriate box below if the Form 8-K filing is wing provisions: Written communications pursuant to Rule 425 under	intended to simultaneously satisfy the filing ob the Securities Act (17 CFR 230.425) e Exchange Act (17 CFR 240.14a-12)	
follo	ck the appropriate box below if the Form 8-K filing is wing provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the	intended to simultaneously satisfy the filing ob the Securities Act (17 CFR 230.425) e Exchange Act (17 CFR 240.14a-12) dle 14d-2(b) under the Exchange Act (17 CFR 2	40.14d-2(b))
follo	k the appropriate box below if the Form 8-K filing is wing provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Rule Pre-comm	intended to simultaneously satisfy the filing ob the Securities Act (17 CFR 230.425) e Exchange Act (17 CFR 240.14a-12) dle 14d-2(b) under the Exchange Act (17 CFR 2	40.14d-2(b))
follo	k the appropriate box below if the Form 8-K filing is wing provisions: Written communications pursuant to Rule 425 under Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Ru	intended to simultaneously satisfy the filing ob the Securities Act (17 CFR 230.425) e Exchange Act (17 CFR 240.14a-12) dle 14d-2(b) under the Exchange Act (17 CFR 2	40.14d-2(b))

Item 7.01 Regulation FD Disclosure.

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors at various times between December 1, 2021 and December 31, 2021. During the meetings, the Company intends to reaffirm its guidance of approximately \$23.67 in diluted earnings per common share ("EPS"), or approximately \$20.50 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2021 ("FY 2021"). This guidance is consistent with the guidance issued in Humana's press release dated November 3, 2021. The date and time of presentations to investors are available via the Investor Relations calendar of events on Humana's website at humana.com.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company's ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company's business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

Diluted earnings per common share	FY 2021 Guidance
GAAP	~\$23.67
Amortization of identifiable intangibles	~0.39
Gain on Kindred at Home equity method investment	(8.73)
Put/call valuation adjustments associated with company's non-consolidating minority interest investments	3.38
Transaction and integration costs associated with the Kindred at Home acquisition	0.61
Change in fair market value of publicly-traded equity securities	1.18
Adjusted (non-GAAP) – FY 2021 projected	~\$20.50

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.

BY: /s/ Cynthia H. Zipperle

Cynthia H. Zipperle

Senior Vice President, Chief Accounting Officer and Controller

(Principal Accounting Officer)

Dated: December 1, 2021